使用68Ga标记抑制剂进行PARP表达的PET显像
本研究设计、合成并评估了三种基于PARP抑制剂奥拉帕尼的68Ga标记放射性探针,放射化学纯度>97%,在SK-OV-3细胞和肿瘤模型中评估了体外摄取与体内PET/CT显像,68Ga-DOTA-奥拉帕尼肿瘤摄取显著高于其他68Ga标记探针,阻断组T/M比值显著低于未阻断组。
要点
- 三种68Ga标记PARP探针放射化学纯度>97%,稳定性好。
- SK-OV-3细胞对三种探针的摄取显著高于A549细胞。
- 68Ga-DOTA-奥拉帕尼肿瘤摄取显著高于其他68Ga标记探针。
核心结论
- 68Ga-DOTA-奥拉帕尼是首个68Ga标记PARP抑制剂,在肿瘤模型中显示高稳定性和快速PARP显像,是有望用于个体化PARP抑制剂治疗方案的显像剂。
研究设计与样本
- 基于PARP抑制剂奥拉帕尼设计、合成并评估了三种靶向PARP的放射性探针,进行了体外和体内评估。
主要发现
- 前体未失去对PARP的结合亲和力,以高放射化学纯度(>97%)进行68Ga标记,68Ga标记放射性示踪剂稳定。
- 由于SK-OV-3细胞中PARP-1表达增加,三种放射性示踪剂在SK-OV-3细胞中的摄取显著大于A549细胞。
- SK-OV-3模型的PET/CT显像显示,68Ga-DOTA-奥拉帕尼的肿瘤摄取(0.5小时:2.83 ± 0.55%ID/g;1小时:2.37 ± 0.64%ID/g)显著高于其他68Ga标记放射性示踪剂。
- 根据PET/CT图像计算的T/M(肿瘤与肌肉)比值在未阻断组与阻断组之间差异显著(4.07 ± 1.01 vs. 1.79 ± 0.45,P = 0.0238 < 0.05)。
- 肿瘤放射自显影显示肿瘤组织中有高蓄积,进一步证实上述数据;免疫组化证实肿瘤中PARP-1表达。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Imaging the PARP expression using 18F probes has been approved in clinical trials. Nevertheless, hepatobiliary clearance of both 18F probes hindered their application in monitoring abdominal lesions. Our novel 68Ga-labelled probes aim for fewer abdominal signals while ensuring PARP targeting by optimizing the pharmacokinetic properties of radioactive probes. METHODS: Three radioactive probes targeted PARP were designed, synthesized, and evaluated based on the PARP inhibitor Olaparib. These 68Ga-labelled radiotracers were assessed in vitro and in vivo. RESULTS: Precursors that did not lose binding affinity for PARP were designed, synthesized, and then labelled with 68Ga in high radiochemical purity (> 97%). The 68Ga-labelled radiotracers were stable. Due to the increased expression of PARP-1 in SK-OV-3 cells, the uptake of the three radiotracers by SK-OV-3 cells was significantly greater than that by A549 cells. PET/CT imaging of the SK-OV-3 models indicated that the tumor uptake of 68Ga-DOTA-Olaparib (0.5 h: 2.83 ± 0.55%ID/g; 1 h: 2.37 ± 0.64%ID/g) was significantly higher than that of the other 68Ga-labelled radiotracers. There was a significant difference in the T/M (tumor-to-muscle) ratios between the unblocked and blocked groups as calculated from the PET/CT images (4.07 ± 1.01 vs. 1.79 ± 0.45, P = 0.0238 < 0.05). Tumor autoradiography revealed high accumulation in tumor tissues, further confirming the above data. PARP-1 expression in the tumor was confirmed by immunochemistry. CONCLUSION: As the first 68Ga-labelled PARP inhibitor, 68Ga-DOTA-Olaparib displayed high stability and quick PARP imaging in a tumor model. This compound is thus a promising imaging agent that can be used in a personalized PARP inhibitor treatment regimen.
引用
- Wang X, Liu W, Li K, et al. PET imaging of PARP expression using 68Ga-labelled inhibitors. Eur J Nucl Med Mol Imaging. 2023. PMID: 37145164. doi:10.1007/s00259-023-06249-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。